Terms: = Breast cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Prognosis
245 results:
1. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
3. eEF1A2 promotes pten-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer.
Treekitkarnmongkol W; Solis LM; Sankaran D; Gagea M; Singh PK; Mistry R; Nguyen T; Kai K; Liu J; Sasai K; Jitsumori Y; Liu J; Nagao N; Stossi F; Mancini MA; Wistuba II; Thompson AM; Lee JM; Cadiñanos J; Wong KK; Abbott CM; Sahin AA; Liu S; Katayama H; Sen S
Sci Signal; 2024 Mar; 17(826):eadh4475. PubMed ID: 38442201
[TBL] [Abstract] [Full Text] [Related]
4. The interplay of pten and AKT nexus in breast cancer: a molecular perspective.
Kamal A; Awan AR; Rabbani M; Sheikh HR; Tayyab M; Firyal S; Khan IH; Wasim M
Mol Biol Rep; 2024 Feb; 51(1):345. PubMed ID: 38400870
[TBL] [Abstract] [Full Text] [Related]
5. A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules.
Iragavarapu-Charyulu V; Shakya R; Robinson P; Guzmán E; Tyulmenkova A; Pino JL; Isgor C
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38131223
[TBL] [Abstract] [Full Text] [Related]
6. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
7. Triptolide Reduces MDA-MB-231 Cell Metastasis by Attenuating Epithelial-Mesenchymal Transition through the ROCK/pten/Akt Axis.
Wu Q; Leng X; Ma X; Xu Q; Ni R; Pan Y; Jin Z; Kalim M
Chem Biodivers; 2023 Dec; 20(12):e202300399. PubMed ID: 37910661
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
[TBL] [Abstract] [Full Text] [Related]
9. Genetic Aspects of Conjunctival Melanoma: A Review.
Chang E; Demirci H; Demirci FY
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761808
[TBL] [Abstract] [Full Text] [Related]
10. Mutation Profile via Next-Generation Sequencing in Patients with Colorectal Adenocarcinoma and Its Clinicopathological Correlation.
Osman S; Kahraman Çetin N; Erdoğdu İH; Meteoğlu İ
Turk J Gastroenterol; 2023 Nov; 34(11):1124-1133. PubMed ID: 37737217
[TBL] [Abstract] [Full Text] [Related]
11. MYC Deregulation and pten Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative breast cancer.
Doha ZO; Wang X; Calistri NL; Eng J; Daniel CJ; Ternes L; Kim EN; Pelz C; Munks M; Betts C; Kwon S; Bucher E; Li X; Waugh T; Tatarova Z; Blumberg D; Ko A; Kirchberger N; Pietenpol JA; Sanders ME; Langer EM; Dai MS; Mills G; Chin K; Chang YH; Coussens LM; Gray JW; Heiser LM; Sears RC
Nat Commun; 2023 Sep; 14(1):5665. PubMed ID: 37704631
[TBL] [Abstract] [Full Text] [Related]
12. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
[TBL] [Abstract] [Full Text] [Related]
13. RARRES2 regulates lipid metabolic reprogramming to mediate the development of brain metastasis in triple negative breast cancer.
Li YQ; Sun FZ; Li CX; Mo HN; Zhou YT; Lv D; Zhai JT; Qian HL; Ma F
Mil Med Res; 2023 Jul; 10(1):34. PubMed ID: 37491281
[TBL] [Abstract] [Full Text] [Related]
14. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH; Im SA; Park K; Wen J; Lee KH; Choi YL; Lee WC; Min A; Bonato V; Park S; Ram S; Lee DW; Kim JY; Lee SK; Lee WW; Lee J; Kim M; Kim HS; Weinrich SL; Ryu HS; Kim TY; Dann S; Kim YJ; Fernandez DR; Koh J; Wang S; Park SY; Deng S; Powell E; Ravi RK; Bienkowska J; Rejto PA; Park WY; Kan Z
Genome Med; 2023 Jul; 15(1):55. PubMed ID: 37475004
[TBL] [Abstract] [Full Text] [Related]
15. Targeting of HBP1/TIMP3 axis as a novel strategy against breast cancer.
Zhou Y; Zhang T; Wang S; Yang R; Jiao Z; Lu K; Li H; Jiang W; Zhang X
Pharmacol Res; 2023 Aug; 194():106846. PubMed ID: 37414199
[TBL] [Abstract] [Full Text] [Related]
16. Mutational signatures for breast cancer diagnosis using artificial intelligence.
Odhiambo P; Okello H; Wakaanya A; Wekesa C; Okoth P
J Egypt Natl Canc Inst; 2023 May; 35(1):14. PubMed ID: 37184779
[TBL] [Abstract] [Full Text] [Related]
17. The impact of PIK3CA mutations and pten expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
Hayama S; Nakamura R; Ishige T; Sangai T; Sakakibara M; Fujimoto H; Ishigami E; Masuda T; Nakagawa A; Teranaka R; Ota S; Itoga S; Yamamoto N; Nagashima T; Otsuka M
BMC Cancer; 2023 Apr; 23(1):384. PubMed ID: 37106324
[TBL] [Abstract] [Full Text] [Related]
18. An Immunohistochemical Study of breast cancer Brain Metastases: The Role of CD44 and AKT in the prognosis.
Martins Gama J; Caetano Oliveira R; Teixeira P; Silva F; Abrantes C; Figueiredo P; Simões S; Rebelo O; Cipriano MA
Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):318-323. PubMed ID: 37093706
[TBL] [Abstract] [Full Text] [Related]
19. The Heparan Sulfate Proteoglycan Syndecan-1 Triggers breast cancer Cell-Induced Coagulability by Induced Expression of Tissue Factor.
Hassan N; Bückreiß N; Efing J; Schulz-Fincke M; König P; Greve B; Bendas G; Götte M
Cells; 2023 Mar; 12(6):. PubMed ID: 36980251
[TBL] [Abstract] [Full Text] [Related]
20. Bioinformatic miRNA-mRNAs Analysis Revels to miR-934 as a Potential Regulator of the Epithelial-Mesenchymal Transition in Triple-Negative breast cancer.
Contreras-Rodríguez JA; Puente-Rivera J; Córdova-Esparza DM; Nuñez-Olvera SI; Silva-Cázares MB
Cells; 2023 Mar; 12(6):. PubMed ID: 36980175
[TBL] [Abstract] [Full Text] [Related]
[Next]
